Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer

  • Moutinho, Cátia
  • Martínez Cardús, Anna
  • Santos, Cristina
  • Navarro Perez, Valentin
  • Martínez Balibrea, Eva
  • Musulén, Eva
  • Carmona, F. Javier
  • Sartore-Bianchi, Andrea
  • Cassingena, Andrea
  • Siena, Salvatore
  • Élez, Elena
  • Tabernero Caturla, Josep
  • Salazar Soler, Ramón
  • Abad, Albert
  • Esteller, Manel, 1968-
BACKGROUND: A major problem in cancer chemotherapy is the existence of primary resistance and/or the acquisition of secondary resistance. Many cellular defects contribute to chemoresistance, but epigenetic changes can also be a cause. METHODS: A DNA methylation microarray was used to identify epigenetic differences in oxaliplatin-sensitive and -resistant colorectal cancer cells. The candidate gene SRBC was validated by single-locus DNA methylation and expression techniques. Transfection and short hairpin experiments were used to assess oxaliplatin sensitivity. Progression-free survival (PFS) and overall survival (OS) in metastasic colorectal cancer patients were explored with Kaplan-Meier and Cox regression analyses. All statistical tests were two-sided. RESULTS: We found that oxaliplatin resistance in colorectal cancer cells depends on the DNA methylation-associated inactivation of the BRCA1 interactor SRBC gene. SRBC overexpression or depletion gives rise to sensitivity or resistance to oxaliplatin, respectively. SRBC epigenetic inactivation occurred in primary tumors from a discovery cohort of colorectal cancer patients (29.8%; n = 39 of 131), where it predicted shorter PFS (hazard ratio [HR] = 1.83; 95% confidence interval [CI] = 1.15 to 2.92; log-rank P = .01), particularly in oxaliplatin-treated case subjects for which metastasis surgery was not indicated (HR = 1.96; 95% CI = 1.13 to 3.40; log-rank P = .01). In a validation cohort of unresectable colorectal tumors treated with oxaliplatin (n = 58), SRBC hypermethylation was also associated with shorter PFS (HR = 1.90; 95% CI = 1.01 to 3.60; log-rank P = .045). CONCLUSIONS: These results provide a basis for future clinical studies to validate SRBC hypermethylation as a predictive marker for oxaliplatin resistance in colorectal cancer.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Epigenetic homogeneity within colorectal tumors predicts shorter relapse-free and overall survival times for patients with locoregional cancer

  • Martínez Cardús, Anna
  • Moran, Sebastian
  • Musulén, Eva
  • Moutinho, Cátia
  • Manzano, José Luis
  • Martínez Balibrea, Eva
  • Tierno, Montserrat
  • Élez, Elena
  • Landolfi, Stefania
  • Lorden, Patricia
  • Arribas, Carles
  • Müller, Fabian
  • Bock, Christoph
  • Esteller, Manel, 1968-
Background & aims: there are few validated biomarkers that can be used to predict outcomes for patients with colorectal cancer. Part of the challenge is the genetic and molecular heterogeneity of colorectal tumors not only among patients, but also within tumors. We have explored intratumor heterogeneity at the epigenetic level, due to its dynamic nature. We analyzed DNA methylation profiles of the digestive tract surface and the central bulk and invasive front regions of colorectal tumors. Methods: we determined the DNA methylation profiles of >450,000 CpG sites in 3 macrodissected regions of 79 colorectal tumors and 23 associated liver metastases, obtained from 2 hospitals in Spain. We also analyzed samples for KRAS and BRAF mutations, 499,170 single nucleotide polymorphisms, and performed immunohistochemical analyses. Results: we observed differences in DNA methylation among the 3 tumor sections; regions of tumor−host interface differed the most from the other tumor sections. Interestingly, tumor samples collected from areas closer to the gastrointestinal transit most frequently shared methylation events with metastases. When we calculated individual coefficients to quantify heterogeneity, we found that epigenetic homogeneity was significantly associated with short time of relapse-free survival (log-rank P = .037) and short time of overall survival (log-rank P = .026) in patients with locoregional colorectal cancer. Conclusions: in an analysis of 79 colorectal tumors, we found significant heterogeneity in patterns of DNA methylation within each tumor; the level of heterogeneity correlates with times of relapse-free and overall survival.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect

  • López Serra, Paula
  • Marcilla, Miguel
  • Villanueva Garatachea, Alberto
  • Ramos Fernandez, Antonio
  • Palau, Anna
  • Leal, Lucía
  • Wahi, Jessica E.
  • Setién, Fernando
  • Szczesna, Karolina
  • Moutinho, Cátia
  • Martínez Cardús, Anna
  • Heyn, Holger
  • Sandoval, Juan
  • Puertas, Sara
  • Vidal-Bel, August
  • Sanjuan, Xavier
  • Martínez Balibrea, Eva
  • Viñals Canals, Francesc
  • Perales Losa, Carlos
  • Bramsem, Jesper B.
  • Ørntoft, Torben F.
  • Andersen, Claus L.
  • Tabernero Caturla, Josep
  • McDermott, Ultan
  • Boxer, Matthew B.
  • Vander Heiden, Matthew G.
  • Albar, Juan Pablo
  • Esteller, Manel, 1968-
Cancer cells possess aberrant proteomes that can arise by the disruption of genes involved in physiological protein degradation. Here we demonstrate the presence of promoter CpG island hypermethylation-linked inactivation of DERL3 (Derlin-3), a key gene in the endoplasmic reticulum-associated protein degradation pathway, in human tumours. The restoration of in vitro and in vivo DERL3 activity highlights the tumour suppressor features of the gene. Using the stable isotopic labelling of amino acids in cell culture workflow for differential proteome analysis, we identify SLC2A1 (glucose transporter 1, GLUT1) as a downstream target of DERL3. Most importantly, SLC2A1 overexpression mediated by DERL3 epigenetic loss contributes to the Warburg effect in the studied cells and pinpoints a subset of human tumours with greater vulnerability to drugs targeting glycolysis.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect

  • López Serra, Paula
  • Marcilla, Miguel
  • Villanueva Garatachea, Alberto
  • Ramos Fernandez, Antonio
  • Palau, Anna
  • Leal, Lucía
  • Wahi, Jessica E.
  • Setién, Fernando
  • Szczesna, Karolina
  • Moutinho, Cátia
  • Martínez Cardús, Anna
  • Heyn, Holger
  • Sandoval, Juan
  • Puertas, Sara
  • Vidal-Bel, August
  • Sanjuan, Xavier
  • Martínez Balibrea, Eva
  • Viñals Canals, Francesc
  • Perales Losa, Carlos
  • Bramsem, Jesper B.
  • Ørntoft, Torben F.
  • Andersen, Claus L.
  • Tabernero Caturla, Josep
  • McDermott, Ultan
  • Boxer, Matthew B.
  • Vander Heiden, Matthew G.
  • Albar, Juan Pablo
  • Esteller, Manel, 1968-
Cancer cells possess aberrant proteomes that can arise by the disruption of genes involved in physiological protein degradation. Here we demonstrate the presence of promoter CpG island hypermethylation-linked inactivation of DERL3 (Derlin-3), a key gene in the endoplasmic reticulum-associated protein degradation pathway, in human tumours. The restoration of in vitro and in vivo DERL3 activity highlights the tumour suppressor features of the gene. Using the stable isotopic labelling of amino acids in cell culture workflow for differential proteome analysis, we identify SLC2A1 (glucose transporter 1, GLUT1) as a downstream target of DERL3. Most importantly, SLC2A1 overexpression mediated by DERL3 epigenetic loss contributes to the Warburg effect in the studied cells and pinpoints a subset of human tumours with greater vulnerability to drugs targeting glycolysis.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Epigenetic homogeneity within colorectal tumors predicts shorter relapse-free and overall survival times for patients with locoregional cancer

  • Martínez Cardús, Anna
  • Moran, Sebastian
  • Musulén, Eva
  • Moutinho, Cátia
  • Manzano, José Luis
  • Martínez Balibrea, Eva
  • Tierno, Montserrat
  • Élez, Elena
  • Landolfi, Stefania
  • Lorden, Patricia
  • Arribas, Carles
  • Müller, Fabian
  • Bock, Christoph
  • Esteller, Manel
Background & aims: there are few validated biomarkers that can be used to predict outcomes for patients with colorectal cancer. Part of the challenge is the genetic and molecular heterogeneity of colorectal tumors not only among patients, but also within tumors. We have explored intratumor heterogeneity at the epigenetic level, due to its dynamic nature. We analyzed DNA methylation profiles of the digestive tract surface and the central bulk and invasive front regions of colorectal tumors. Methods: we determined the DNA methylation profiles of >450,000 CpG sites in 3 macrodissected regions of 79 colorectal tumors and 23 associated liver metastases, obtained from 2 hospitals in Spain. We also analyzed samples for KRAS and BRAF mutations, 499,170 single nucleotide polymorphisms, and performed immunohistochemical analyses. Results: we observed differences in DNA methylation among the 3 tumor sections; regions of tumor−host interface differed the most from the other tumor sections. Interestingly, tumor samples collected from areas closer to the gastrointestinal transit most frequently shared methylation events with metastases. When we calculated individual coefficients to quantify heterogeneity, we found that epigenetic homogeneity was significantly associated with short time of relapse-free survival (log-rank P = .037) and short time of overall survival (log-rank P = .026) in patients with locoregional colorectal cancer. Conclusions: in an analysis of 79 colorectal tumors, we found significant heterogeneity in patterns of DNA methylation within each tumor; the level of heterogeneity correlates with times of relapse-free and overall survival.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer

  • Moutinho, Cátia
  • Martínez Cardús, Anna
  • Santos, Cristina
  • Navarro Perez, Valentin
  • Martínez Balibrea, Eva
  • Musulén, Eva
  • Carmona, F. Javier
  • Sartore-Bianchi, Andrea
  • Cassingena, Andrea
  • Siena, Salvatore
  • Élez, Elena
  • Tabernero Caturla, Josep
  • Salazar Soler, Ramón
  • Abad, Albert
  • Esteller, Manel, 1968-
BACKGROUND: A major problem in cancer chemotherapy is the existence of primary resistance and/or the acquisition of secondary resistance. Many cellular defects contribute to chemoresistance, but epigenetic changes can also be a cause. METHODS: A DNA methylation microarray was used to identify epigenetic differences in oxaliplatin-sensitive and -resistant colorectal cancer cells. The candidate gene SRBC was validated by single-locus DNA methylation and expression techniques. Transfection and short hairpin experiments were used to assess oxaliplatin sensitivity. Progression-free survival (PFS) and overall survival (OS) in metastasic colorectal cancer patients were explored with Kaplan-Meier and Cox regression analyses. All statistical tests were two-sided. RESULTS: We found that oxaliplatin resistance in colorectal cancer cells depends on the DNA methylation-associated inactivation of the BRCA1 interactor SRBC gene. SRBC overexpression or depletion gives rise to sensitivity or resistance to oxaliplatin, respectively. SRBC epigenetic inactivation occurred in primary tumors from a discovery cohort of colorectal cancer patients (29.8%; n = 39 of 131), where it predicted shorter PFS (hazard ratio [HR] = 1.83; 95% confidence interval [CI] = 1.15 to 2.92; log-rank P = .01), particularly in oxaliplatin-treated case subjects for which metastasis surgery was not indicated (HR = 1.96; 95% CI = 1.13 to 3.40; log-rank P = .01). In a validation cohort of unresectable colorectal tumors treated with oxaliplatin (n = 58), SRBC hypermethylation was also associated with shorter PFS (HR = 1.90; 95% CI = 1.01 to 3.60; log-rank P = .045). CONCLUSIONS: These results provide a basis for future clinical studies to validate SRBC hypermethylation as a predictive marker for oxaliplatin resistance in colorectal cancer.